Drugs / VGO-Cs01p
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06849401 | Jul 2025 → Aug 2026 overdue | T-cell acute lymphoblastic leukemia | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VGO-Cs01p | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06849401 ↗ |
| Modality | Cell therapy | “Off-the-shelf NK cell products derived from human embryonic stem cells (hESCs)” NCT06849401 ↗ |
| Target | CD7 | “CD7 CAR NK cells” NCT06849401 ↗ |